IDDI Complimentary Breakfast Webinar

November 19, 2020

IDDI Breakfast Banner
Drug development in oncology in the era of precision medicine
08:30am – 09:30am (CET), 19th NOVEMBER, 2020


Please fill out the below form and we’ll send you the presentation slides, along with a summary of the quick polls from our presentation, and the questions and responses for the Q&A portion. 


    I authorize IDDI to use my data to contact me for commercial purposes.More information


    IDDI is pleased to invite you to an exclusive breakfast webinar discussing drug development in oncology, enhanced by the presence of Christophe Le Tourneau, MD, PhD as Keynote Speaker.

    Enjoy your morning coffee and start your day with an insightful presentation with Christophe Le Tourneau, one of the most recognized key opinion leaders in Oncology.

    • A better knowledge of cancer biology that has led to a molecular segmentation of cancer

    • New clinical trial designs that have been set up in order to overcome the challenge of small molecularly-defined patient populations: these trials include basket trials (histologic stratification) and umbrella trials (molecular stratification), but also trials that mix tumor types, targets and drugs that only assess the efficiency of the treatment algorithm used to allocate drugs to patients

    • Challenges of these designs will be discussed, as well as perspectives on how to speed up drug development in the era of precision medicine


    Christophe Le Tourneau, MD, PhD:
    Senior Medical Oncologist at the Institut Curie and Full Professor of Medicine at Paris-Saclay University

    Christophe is heading the Department of Drug Development and Innovation (D3i) as well as the Head and Neck Clinic. He is leading the early phase clinical trials program of the Institut Curie. His main interests are precision medicine, phase I clinical trials with a special attention at the methodology to conduct these trials, as well as Head and Neck oncology. Christophe is also the principal investigator of numerous phase I and II trials, as well as of clinical trials in Head and Neck oncology. He is also leading several precision medicine projects.

    Christophe has participated in the Developmental Therapeutics track of the ASCO from 2017 to 2019 and has been the track leader in 2018. He has been a member of the Developmental Therapeutics and the Head and Neck Cancer tracks on several occasions.